Pfizer Inc banner

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 26.79 USD -0.78% Market Closed
Market Cap: $152.4B

Pfizer Inc
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Pfizer Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Other Long-Term Assets
$19.3B
CAGR 3-Years
-1%
CAGR 5-Years
28%
CAGR 10-Years
14%
Johnson & Johnson
NYSE:JNJ
Other Long-Term Assets
$19.3B
CAGR 3-Years
3%
CAGR 5-Years
8%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Other Long-Term Assets
$8.2B
CAGR 3-Years
42%
CAGR 5-Years
20%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Other Long-Term Assets
$17.8B
CAGR 3-Years
30%
CAGR 5-Years
13%
CAGR 10-Years
11%
Zoetis Inc
NYSE:ZTS
Other Long-Term Assets
$965m
CAGR 3-Years
44%
CAGR 5-Years
37%
CAGR 10-Years
22%
Eli Lilly and Co
NYSE:LLY
Other Long-Term Assets
$17B
CAGR 3-Years
33%
CAGR 5-Years
22%
CAGR 10-Years
23%
No Stocks Found

Pfizer Inc
Glance View

Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.

PFE Intrinsic Value
31.36 USD
Undervaluation 15%
Intrinsic Value
Price $26.79

See Also

What is Pfizer Inc's Other Long-Term Assets?
Other Long-Term Assets
19.3B USD

Based on the financial report for Dec 31, 2025, Pfizer Inc's Other Long-Term Assets amounts to 19.3B USD.

What is Pfizer Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
14%

Over the last year, the Other Long-Term Assets growth was 5%. The average annual Other Long-Term Assets growth rates for Pfizer Inc have been -1% over the past three years , 28% over the past five years , and 14% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett